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The magnitude of negative selection on alleles involved in age-specific mortality decreases with age. This is the foundation of
the evolutionary theory of senescence. Because of this decrease in negative selection with age, and because of the absence of
reproduction after menopause, alleles involved in women’s late-onset diseases are generally considered evolutionarily neutral.
Recently, genetic and epidemiological data on alleles involved in late onset-diseases have become available. It is therefore
timely to estimate selection on these alleles. Here, we estimate selection on BRCA1 alleles leading to susceptibility to late-
onset breast and ovarian cancer. For this, we integrate estimates of the risk of developing a cancer for BRCA1-carriers into
population genetics frameworks, and calculate selection coefficients on BRCA1 alleles for different demographic scenarios
varying across the extent of human demography. We then explore the magnitude of negative selection on alleles leading to
a diverse range of risk patterns, to capture a variety of late-onset diseases. We show that BRCA1 alleles may have been under
significant negative selection during human history. Although the mean age of onset of the disease is long after menopause,
variance in age of onset means that there are always enough cases occurring before the end of reproductive life to
compromise the selective value of women carrying a susceptibility allele in BRCA1. This seems to be the case for an extended
range of risk of onset functions varying both in mean and variance. This finding may explain the distribution of BRCA1 alleles’
frequency, and also why alleles for many late-onset diseases, like certain familial forms of cancer, coronary artery diseases and
Alzheimer dementia, are typically recent and rare. Finally, we discuss why the two most popular evolutionary theories of aging,
mutation accumulation and antagonistic pleiotropy, may underestimate the effect of selection on survival at old ages.
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INTRODUCTION
Evolutionary theories of senescence (i.e. the increasing risk of
death at older ages) are based on the fact that selection pressures
on mortality diminish with age. This is because genes expressed at
a specific age only affect individuals which survive to this age, who
account for a decreasing proportion of the population as age
increases. These theories assume therefore that mutations in-
creasing mortality late in life are either subject: 1) to very small
negative selection and can therefore accumulate (mutation
accumulation) or 2) to small enough negative selection to be
traded-off against higher fertility or survival at young ages
(antagonistic pleiotropy). In both cases, deleterious mutations
acting at older ages will persist and their cumulative effects on
mortality will be responsible for senescence. Theoretical models of
these alternatives calculate selection pressures on mortality as
a change in fitness relative to a change in mortality at a specific age
[1], or over a specific range of ages [2,3,4]. Allele frequency
distributions that would result if selection and mutation were in
balance for age-specific alleles have also been provided [3,5].
Genetic research has identified few alleles involved in decreasing
human mortality at old ages [6] but thousands of deleterious alleles
are linked to susceptibility to late-onset diseases. For example, the
Online Mendelian Inheritance in Man Database (OMIM, see
www.ncbi.nlm.nih.gov) records dozens of late-onset diseases linked
to genetic susceptibility; sometimes involving a single gene (e.g.
Huntington’s disease) but often numerous genes (e.g. Alzheimer’s).
Epidemiological data on the age of onset of such genetic diseases
are now available. Surprisingly, no study has used these data to
estimate selection against late-acting deleterious mutations.
However, this would be informative because, although theoretical
models assume a constant change in mortality at a given age or
across a window of ages [1,2,4], genetic diseases show complex
patterns of variability in age of onset. Additionally, assessing
whether a mutation has been selected against in past human
history requires that selection be estimated in realistic de-
mographic scenarios: human demography varies considerably
between populations which can affect both the strength of
selection and genetic drift.
Genetic susceptibility to breast and ovarian cancer in women
arising from a mutation in the BRCA1 gene is one of the most
widespread genetic diseases. Such mutations occur in 1 out of
3000 women in the USA [7], although frequencies vary
considerably among populations [8]. Women with a mutation
have a 65% risk of developing breast cancer before age 70 [9].
Breast and ovarian cancers linked to mutations in BRCA1 are
therefore likely to have been one of the main genetically-related
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mutations can be therefore regarded as important deleterious
mutations involved in old age mortality. It is consequently of
interest to estimate selection on BRCA1 mutations in relevant
demographic scenarios for the light it can shed on senescence.
From the perspective of epidemiological genetics, BRCA1 is
remarkable being highly polymorphic with both rare and frequent
alleles [8]. In 2006, the Breast Cancer Information Core (BIC, see
www.nhgri.nih.gov/Intramural_ research/Lab_transfer/Bic) re-
corded more than 1000 alleles involved in a significantly higher
susceptibility of carriers to develop a breast or ovarian cancer.
Moreover, the frequency distribution of these alleles is highly
heterogeneous [8]. Because the mean age of onset of breast and
ovarian cancer is long after menopause [9], when selection is
considered nonexistent, BRCA1 alleles are generally thought to be
selectively neutral. Mutation frequencies have therefore been
explained by founder effects and population history [8]. Some
mutations accord well with this explanation: for example the allele
185delAG is found in more than 1% of Ashkenazi Jewish women
[10]. However, prevalence of breast cancer is not only associated
with a few frequent mutations resulting from a founder effect, but
also with many rare mutations. For example in Italy, most BRCA1
mutations are at low frequencies and even in most cases recorded
in only one family [8]. More generally, Wright et al. [11]
highlighted that most alleles involved in genetic diseases including
familial forms of cancer (such as breast cancer linked to BRCA1),
coronary artery diseases and Alzheimer dementia, are recent and
rare. These are characteristics of alleles involved in early onset
diseases and subject to selection. Despite the fact that these
diseases generally act after menopause, we would therefore expect
these alleles to show direct or indirect effects on fitness.
In this paper we aim to determine whether BRCA1 mutations
have been neutral or under negative selection in recent human
history. To do this, we incorporate estimates of age of onset of
cancer [9] into a population genetic framework under different
demographic scenarios. This is important because selection will
depend on the proportion of women surviving at ages at which they
are susceptible to develop the disease and the number of offspring
produced by these women. To generalize our conclusions to diseases
characterizedbydifferent patterns of age of onset wealso explorethe
effect of changes in the mean and variance of age of onset on
selection. This required that we 1) obtain parameters for the hazard
of developing cancers for BRCA1 mutation carriers; 2) obtain
demographic parameters of fertility and survival for the populations
considered; 3) determine the mortality hazard of mutation carriers
and non-carriers in these populations; and 4) integrate these hazards
into a population genetics framework to estimate the magnitude of
selection on mutations in BRCA1. We outline these steps below (the
codein‘R’ allowing calculations forsteps 1,3 and4 isprovided inthe
supplementary material entitled Code S1).
METHODS
Hazard of Developing Cancers for BRCA1 Mutation
Carriers
We described the distribution of the age of onset of cancer for
women carrying a BRCA1 mutation by a cumulative distribution
function F(x), (i.e. the cumulative risk of developing a cancer before
age x, p(X#x)). We used data from a recent meta-analysis of 22
studies [9] to obtain the cumulative risk with age x of developing
breast cancer, Fb(x), and ovarian cancer Fo(x), for individuals
carrying a BRCA1-mutation in a population free of any other
causes of death. This risk is an average over all BRCA1
susceptibility alleles. As the risk of developing a breast or an
ovarian cancer increases between age 20 and 49 and then
decreases up to age 69 (no data are available after this age, [9]), we
modeled the cumulative risks Fb(x) and Fo(x) by a 2-parameter
cumulative gamma distribution F(x)~
ðx
0
1
b
aC(a)
xa{1e
{x
b
  
fitted using a non-linear least squares approach from [9]. The
corresponding hazards over ages hb(x) and ho(x) were estimated
using the identity h(x)=F9(x)/(12F(x)), where F9(x) is the
probability density function obtained as the derivative of the
cumulative risk function F(x). Under the assumption that both risks
of developing a breast or an ovarian cancer are independent for
mutation carriers, we estimated the hazard hbo(x) of developing
either breast or ovarian cancer using the competing risks equation
hbo(x)=hb(x)+ho(x). The corresponding cumulative risk Fbo(x) is given
by the identity and was also fitted by a 2-parameter gamma
function (Figure 1). The mean and variance of age of onset
associated with this curve are m=ab=55 and s
2=ab
2=306. As
the hazard hbo(x) is considerably higher for individuals carrying
a mutation than for individuals without a mutation (up to 61 times
higher), the risk for carriers of developing a sporadic cancer (i.e.
not associated with a mutation) can be considered negligible. We
therefore defined hbo(x) as the hazard associated with the risk of
developing a non-sporadic breast or ovarian cancer.
Fertility and Survival for Three Demographic
Scenarios
If current allele frequencies are due to negative selection on
BRCA1-mutations, this negative selection occurred in the past. We
therefore used females’ mortality and fertility estimates for
Figure 1. Age-specific risk of developing the disease. Women’s
cumulative risk of developing breast cancer (dashed line, Fb(x)), ovarian
cancer (dotted line, Fo(x)) or either (solid line, Fbo(x)) in a population free
of any other causes of death. The two functions Fb(x) and Fo(x) are fitted
2-parameter cumulative gamma distributions from data from [9]. For
breast cancer, Fb(x), a=7.93 and b=7.54; and for ovarian cancer, Fo(x),
a=8.20 and b=9.86. The cumulative gamma function associated with
this risk Fbo(x) has parameters a=9.97 and b=5.54.
doi:10.1371/journal.pone.0001206.g001
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1) the population of early Quebec, 17th to 18th century French
Canadians [12, pp. 131 and 88]; 2) the Ache, a population of
hunter-gatherers from the Amazonian forests of Latin America
[13, pp. 196 and 261] and 3) a theoretical stationary population
with low life-expectancy and low fertility intended to capture
human demography under extremely harsh conditions (Population
type West, mortality level 1 and mean age at maternity in absence
of death equals 27 years from [14, pp. 8 and 30]). These three
demographic scenarios cover a wide range of demographic
parameter space for adult survival and fertility. Their attributes
can be summarized by two variables: remaining life-expectancy at
age 10 of survivors at this age, e0
10; and mean number of daughters
born to a woman surviving at age 50, Gross Replacement Rate
(GRR). The population of Quebec has high adult survival and very
high fertility (e0
10~49 years and GRR~6:125); the Ache popu-
lation has intermediate adult survival and fertility (Ache,e0
10~
46:51 and GRR~4:016) and the modeled population is an
extreme case of a stationary population with very low adult
survival and fertility (e0
10~29 and GRR~1:288). Data from life-
and fertility-tables [12,13,14] were fitted using a non-linear least
squares approach. As children with a mutation in BRCA1 do not
develop cancer before the onset of reproduction, and as fertility is
zero after age 50, survival before 10 and after 50 will not alter the
selection coefficient. Adult women’s survival was therefore
modeled from age 10 to age 50 using a Gompertz-Makeham
function, S(x)~e
a
b(1{eb(x{D)){cx, (Figure 2A).
We modeled fertility rates M(x) by a Hadwiger function [15],
M(x)~TFR½
h1
h3
ﬃﬃﬃ
p
p (
h3
x{h1
)
3=2exp({h2
2 (
h3
x{h1
z
x{h1
h3
{2)) , ð1Þ
where TFR is the total fertility rate estimated from data and where
h1, h2, and h3 have no particular demographic interpretation (but
see [16] for calculation of the mean, the variance and the median
of the density function for a Hadwiger distribution). This function
was fitted for fertility rates between ages 10 and 49 and equal to
0 for younger and older ages respectively (Figure 2B). The
Hadwiger function is better suited than the Brass function, for
example, as it better captures late life fertility in pre-industrial
populations [16].
Mortality Hazard of Mutation Carriers and
Non-Carriers
We needed to establish survival of BRCA1 mutation carriers and
non-carriers in the three demographic scenarios considered. In
any population, the overall mortality hazard at age x, h
pop(x), is the
sum of the proportion of non-carriers p
NC(x) times their mortality
hazard h
NC(x) and the analogous product for carriers p
C(x)h
C(x)
defined as:
hpop(x)~pNC(x)hNC(x)zpC(x)hC(x) ð2Þ
where p
NC(x) and p
C(x) are the proportion of non-carriers and
carriers in any age-class x such that p
NC(x)+p
C(x)=1; and h
NC(x)
and h
C(x) are their respective mortality hazards at age x.T o
establish the mortality hazard of mutation carriers for integration
into the considered demographic contexts, we first assumed that all
individuals who develop a cancer die in the absence of modern
medicine. The hazard of developing a breast or ovarian cancer
hbo(x) is therefore a mortality hazard. Note that the data used to
obtain the corresponding cumulative risk of death of mutation
carriers Fbo(x) above is based on age at diagnosis which is necessarily
earlier than the expected age at death. Our analysis does not
distinguish these ages and therefore underestimates the mean age of
death. Second, we assumed that there is no interaction between
genes and the environment: i.e., the hazard of carriers hbo(x)
estimated from [9] would be the same if estimated in any other
environment. Third, we assumed independence between the risk of
dying of a cancer resulting from a BRCA1 mutation and the risks of
any other causes of death (i.e. the corresponding mortality hazards
are independent). With these three assumptions, hbo(x) can be added
tothemortalityhazardofanyothercausesofdeathinthepopulation
considered (denoted ha(x)) to calculate the overall mortality hazard of
BRCA1 mutation carriers, h
C(x)=hbo(x)+ha(x). As non-carriers do not
experience the mortality risk associated with non-sporadic breast or
ovarian cancer hazard hbo(x), their overall mortality hazard h
NC(x)i s
simply ha(x). Equation 2 becomes:
hpop(x)~pNC(x)ha(x)zpC(x)(ha(x)zhbo(x)) ð3Þ
The mortality hazard observed for the populations considered
Figure 2. Demographic scenarios. Adult women’s survival (A) and
fertility (B) from ages 10 to 50 for the population of early Quebec (solid
line), the Ache (dashed line) and the modeled population (dotted line).
These populations differ by their growth (respectively high, interme-
diate and stationary, see [12,13,14]). Female adults’ age-specific
survivals were modeled by a Gompertz-Makeham. For Quebec,
a=4.69610
24, b=7.28610
22, D=0 and c=1.49610
23. For the Ache,
a=3.00 610
25, b=1.10 610
21, D=0 and c=6.33 610
23.F o rt h e
modeled population, a=1.99 610
23, b=5.82 610
22, D=10 and
c=1.2610
22. Female adults’ fertilities were modeled by a Hadwiger
function. For Quebec, TFR=12.25, h1=2246.92, h2=18.72, h3=272.77.
For the Ache, TFR=8.032, h1=236.82, h2=4.79, h3=68.29. For the
modeled population TFR=2.578, h1=27.61, h2=3.31, h3=34.31.
doi:10.1371/journal.pone.0001206.g002
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population containing both non-carriers and carriers, the proportion
of carriers p
C(x) in a cohort will change with time due to their higher
mortality so that there are increasingly fewer carriers at higher ages.
This is a problem because, at any age, the mortality hazard observed
in the population depends on the proportion of carriers and non-
carriers at this age and these proportions are not known. However,
except for populations with founder effects, the prevalence of cancer
due to genetic susceptibility linked to BRCA1 is unlikely to be greater
than1 in3000[8].Theproportion of carriersrelative to non-carriers
can therefore be for simplicity considered negligible at all ages
(p
NC(x)..p
C(x)f o ra n yx). The overall mortality hazard of the
population h
pop(x) provides us therefore with that of non-carriers
h
NC(x):
hpop(x)~hNC(x)~ha(x) ð4Þ
Consequently, for any population considered, the mortality hazard
of non-carriers is simply h
NC(x)=h
pop(x), and the mortality hazard of
carriers is h
C(x)=h
pop(x)+hbo(x).
Estimation of the Magnitude of Selection on
Mutations in BRCA1
We needed to insert the demographic parameters obtained above
into a population genetics framework to estimate selection. BRCA1
is a tumor suppressor gene. A germline mutation in BRCA1 occurs
when one copy of the gene in a pair of homologues experiences
a loss of function. A somatic mutation leading to the loss of
function of the second gene in the pair completes the loss of
function and renders the gene ineffective (i.e., the Loss of
Heterozygocity, [17]). This second somatic mutation seems
inevitable [17]: transmission of a single germinal copy of the gene
is sufficient to result in predisposition to cancer. Genetic
transmission of susceptibility to breast or ovarian cancer linked
to the locus BRCA1 is therefore dominant. We assumed that
women carrying mutations in BRCA1 only differ from those
without by a higher mortality hazard h
C(x).h
NC(x), i.e., mutation
does not alter fertility of carriers relative to non-carriers, and
likewise fertility does not alter susceptibility to cancer for carriers.
These hazards correspond to two different survival functions S
C(x)
and S
NC(x) such that S(x)~e
{
Ð x
0 h(x). The average number of
children produced by a woman during her lifetime W can then be
calculated as the sum over all ages of the product between the
survival Sx and fertility rates Mx for carriers and non-carriers
respectively, WNC~
P
x SNC
x Mx and WC~
P
x SC
x Mx. Assum-
ing that the mutation is rare, the selection coefficient associated
with the mutation is then given by s~1{
WC
WNC. Negative selection
against the mutation will largely override the effect of genetic drift
if 2Nes.10, where Ne is effective population size (an estimate of the
number of breeders), and s is the coefficient of selection defined
above [18]. In other words, a deleterious mutation subject to
negative selection such that 2Nes.10 will never go to fixation by
chance through genetic drift, but will eventually be eliminated by
selection. Having estimated s, we then calculated the smallest
effective size required for the effect of negative selection to drive
the mutation extinct (Nemin=10/2s) and compared this with what
it is known about the effective size of human populations to
determine whether selection is strong enough to overcome the
effect of genetic drift. Ne for Quebec is estimated at 1000 [19]. No
estimates of Ne exist for the Ache or the modeled population, but
human populations’ Ne rarely falls below 100, with the exception
of very isolated insular populations [20]. To explore implications
of changes in the mean or variance of age of onset age for the
selection coefficient, we altered both and calculated the resulting s
and Nemin. This allowed us to test how robust our results are to our
assumptions by exploring a range of parameter space; and to
consider implications for a broader range of diseases with different
mean and variance in age of onset.
RESULTS
We found that the minimum effective population size Nemin such
that selection against BRCA1 mutations dominates over drift is 92
(s=0.0541) for Quebec populations, 60 (s=0.0833) for Ache
populations and 130 (s=0.0382) for the modeled population. Most
human populations will generally have higher effective population
sizes than these minimum effective sizes [20]. Consequently,
despite the fact that BRCA1 alleles are classically considered
neutral due to their late age of onset, there is actually strong
selection against them. This is because variance in age of onset
means that younger individuals also develop the disease. Although
most carriers develop the disease after age 45, 27% (Quebec), 24%
(Ache) and 15% (modeled population) of breast and ovarian
cancer cases occurred before this age. Figure 3 shows the
minimum effective size Nemin required for selection to overcome
genetic drift for mutations corresponding to a range of altered
means (Figure 3A) and variances (Figure 3B) of the cumulative risk
Fbo(x) estimated for BRCA1 alleles in the case of the population of
Quebec (red line in Figure 3A and 3C). For most of the range
explored, alleles experience strong negative selection (Nemin,1000)
(Figure 3C). Results also show strong negative selection against
high variance in the age of onset. Although the magnitude of
selection fades quickly for very high mean and very low variance,
the abundance of early cases is sufficient to lead to significant
negative selection even for mean ages of onset occurring far
beyond reproductive cessation (e.g. up to age 70 for the observed
variance and for Ne,1000).
This also means that our results are robust to the assumptions
of our analysis (independence between risk of breast cancer and
ovarian cancer, certain death for individuals who develop
a cancer, no interaction between the risk of non-sporadic cancer
for carriers and the environment, independence between the risk
of cancer and the risk of any other causes of death). Violation of
the assumptions may change the mean and variance of the risk
for carriers, but the magnitude of change is unlikely to extend
beyond the range explored in our analysis (i.e. 15 years around
the mean and a variance spanning from 100 to 800), which is
predominantly in the area where selection overcomes drift (i.e.
Nemin,1000).
The Ache population and the modeled population show very
similar selective patterns to those presented in Figure 3C
(presented in Figure 4 for information). Results are therefore
largely independent of the demographic scenario considered; even
when mortality is very high and late fertility is low. This indicates
that selection has occurred throughout human history. However,
although the magnitude of selection on alleles is strong enough to
overcome genetic drift in all three demographic scenarios
considered, this magnitude nevertheless varies. This will affect
the time to extinction of the mutation but not its fate. We discuss
below (see discussion) which demographic traits most shape these
differences in magnitude of negative selection. Finally these results
do not include intergenerational transfers and negative selection is
thereby underestimated: extending the model to incorporate the
fact that women might contribute to their children’s or grand-
children’s survival through post-natal maternal or grand-maternal
care would strengthen our results [21].
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Population genetics of late-onset-diseases
We demonstrate that variance in age of onset strongly influences
selection on alleles involved in susceptibility to late-onset diseases
that lead to rapid death of carriers. For genetic diseases occurring
in women and characterized by a mean age of onset long after
menopause, cases generally do not occur at a specific age but are
spread across several ages. Consequently, the proportion of cases
arising during reproductive ages may not be negligible with respect
to selection. Using a cumulative risk function averaged over all
BRCA1 alleles, we show that this pattern has resulted in negative
selection on ’the average’ BRCA1 alleles for three different
demographic scenarios, from fast growing populations (high
survival and fertility) to stationary populations (low survival and
fertility): although the mean age of onset occurs after menopause
(55 years old) between 15 and 27% of cases occur before age 45,
allowing negative selection to operate. We therefore show 1) that
negative selection on BRCA1 alleles is likely to have operated
during human history and 2) that negative selection is likely to
apply for most alleles leading to late-onset diseases, as it occurs
across a broad range of mean and variance of age of onset. For
example, any other allele associated with a distribution of age of
onset with a similar variance to that observed for BRCA1 would be
significantly negatively selected against even for a mean age of
onset of up to 70 in a population of effective size 1000 (Figure 3C).
Are the selection coefficients calculated compatible with
observed BRCA1 alleles frequencies? This can be explored
by calculating allele frequencies expected when selection and
mutation are in balance. Homozygous individuals carrying
susceptibility alleles on both chromosomes die before birth. The
selection coefficient for this genotype shomo is therefore 1. For
heterozygotes, the selection coefficient shetero is as calculated above.
It can also be seen as the product of the partial dominance
coefficient of the susceptibility allele h (here the partial dominance
results mainly from Loss Of Heterozygosity) and the selection
coefficient for homozygote carriers shomo. Consequently,
shetero=shomoh=h. In a simple mutation-selection balance model
for partially dominant alleles (in a closed, panmictic, stationary
population with an even sex-ratio), the estimated frequency of
susceptible alleles q is q=m/shetero, where m is the rate at which
susceptibility alleles arise in a new individual. If ,1 woman in
a 1000 carries a germline mutation in BRCA1 at birth
(q=1 610
23), and if these mutations are negatively selected with
a selection coefficient equal to that calculated for Quebec
population (s=0.0541), then the expected deleterious mutation
rate m=qs is 5610
25 germline mutations per new individual. This
mutation rate is in the range of those expected for most coding-
protein genes [22].
How do different demographic scenarios alter estimates
of selection? Results remain consistent across a range of
mortality and fertility schedules broad enough to incorporate
most demographic scenarios possible through Homo sapiens history.
Although the magnitude of selection varies from one to two fold
between the modeled population and the Ache (Nemin equals 60 for
the Ache and 130 for the modeled population), negative selection
remains in a range likely to be efficient in most human populations
[20]. This consistently strong selection arises because the
proportion of children born to women at the end of their
reproductive life relative to their lifetime reproductive success is
not negligible in all three demographic scenarios considered (the
proportion of children born to women older than age 39 is 6% of
the adults’ lifetime reproductive success for Quebec, 11% for the
Ache and 2% for the modeled population). To assess the
importance of fertility rates on selection on BRCA1 susceptibility
alleles, we calculated the Nemin for populations with the survival
trajectory of Quebec and the Ache respectively, but the fertility of
the modeled population (i.e. simulating a large decrease in
fertility). Nemin rose to 112 for Quebec (from 92) and 113 for
Ache (from 60). These differences are due to the fact that the
population of Quebec and the Ache differ mainly through the
higher late fertility rates observed in the Ache: the loss of late-
fertility is therefore larger for Ache than for the population of
Quebec. To assess the importance of survival, we also calculated
the Nemin for populations with the fertility trajectory of Quebec and
the Ache respectively, but survival of the modeled population (i.e.
simulating a large decrease in survival). Nemin rose to 111 for
Quebec (from 92) and 70 for Ache (from 60). These results
indicate that changes in late fertility rates more strongly affect the
Figure 3. Selection on late-onset diseases. To explore a range of
patterns of age of onset, we altered the observed cumulative risk with
age Fbo(x) of developing either breast or ovarian cancer for females
carrying a BRCA1 susceptibility allele estimated from [9] (red line) by
changing the mean from age 40 to 70 (A) and the variance from 100 to
800 (B). This was achieved by altering parameters a and b of the
cumulative gamma. We calculated the minimum effective population
size Nemin=10/2s necessary for negative selection to dominate over
drift [18] corresponding to BRCA1-alleles associated with each of these
curves. These Nemin are shown in (C) for the Quebec population. The
point represents values estimated from [9] for the cumulative risk of
developing breast and ovarian cancer given a mutation in BRCA1
(mean=55; variance=306; Nemin=92).
doi:10.1371/journal.pone.0001206.g003
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fertility rates are likely to be a key demographic feature of past
populations, we expect strong selection against alleles predisposing
to late-onset diseases, even if survival at old ages was low.
Overall, these changes in populations’ demography have a much
lower impact on the fate of a mutation than the effective size of the
population Ne (especially for alleles leading to high mean/low
variance in age of onset, see Figure 3C and 4). Consequently,
variation in the age-trajectories of survival and fertility among
populations do not greatly alter selection on alleles involved in
susceptibility to late-onset diseases (in agreement with results from
[3]), unless such changes alter the effective population size. The
latter is therefore likely to be the key variable affecting the purging
of alleles involved in late onset diseases from human populations.
Can variation in the magnitude of selection explain the
distribution of alleles frequencies observed for
BRCA1? Our results have implications for the genetic
epidemiology of BRCA1.A sBRCA1 mutations have been
selected against in past populations, negative selection may
explain, with genetic drift and population history, the current
geographic distribution of most BRCA1 allele frequencies
characterized by a large number of recent and rare alleles.
However, why then are certain BRCA1 alleles, some of which are
known to have appeared more than 500 years ago still present
[8,23]? Founder effects have been identified in some cases (e.g. for
the 189delAG mutation found in 1% of Ahskenazi Jews, which
appeared 460–1600 years ago), but remain undetected for others
(e.g. for 5382insC, the most common mutation in Russia and
Europe, estimated age of appearance 360–1380 years ago, [8,23]).
A first explanation might be that these BRCA1 mutations have
positive pleiotropic effects on either fertility or early survival.
However, the BRCA1 protein is known to act in DNA repair [24],
and other pleiotropic effects beyond preventing cancer onset are to
date unknown. Alternatively, it is known that different mutations
lead to different risks of developing cancer [25]. Old alleles, still
present at relatively high frequencies, might be characterized by
a higher mean age of onset and/or a lower variance and
consequently be less negatively selected, facilitating their
persistence through drift and migration. Another possibility is
that the risk profile associated with alleles may have changed over
the course of human history. Epidemiological studies have shown
that women’s reproductive trajectories (age at menarche and
menopause, nulliparity, etc.) and nutrition are associated with
variation in breast cancer risk. The interaction between BRCA1
susceptibility alleles and the environment or cultural behavior is
still poorly understood [26] and empirically difficult to access [27],
but inconsistencies between breast and ovarian cancer rates and
mutation frequencies (e.g. [28]) provide some support for Eaton et
al. ’s notion that risks of cancer due to genetic susceptibility were
lower in pre-industrial populations than in current populations
[29]. Some susceptibility alleles may have therefore been under
lower levels of negative selection in particular past environments,
allowing them to reach higher frequencies. Our results are based
on an estimation of the cumulative risk of developing cancers,
averaged over all BRCA1 mutations, and we therefore cannot
differentiate the magnitude of selection acting on different alleles.
Further study could assess if, among these alleles, alleles’
frequencies are correlated with a higher mean and/or a lower
variance in age of onset. If this prediction proved true, the
frequency distribution of alleles could be used (with knowledge of
population demographic history) to make predictions about the
associated variation in risk of onset (between alleles and/or
between environments); and vice versa.
Aging theory
What do our results contribute to theories of
aging? Theoretical models consider that selection pressures on
survival at old ages is small (and even null after menopause for
women) because survival at these ages no longer affects fitness
[1,2,3,4]. We explored a range of parameter space corresponding
to a large range of mean and variance in age of onset that might
correspond to a variety of late onset diseases. Throughout this
range, alleles were subject to considerable negative selection. This
is firstly because age of onset of genetic diseases may be very
variable, so that young individuals may die of the disease even for
diseases with a late average age of onset. It is likely that very few
genetic diseases affecting women late in life fail to affect at least
some pre-menopausal individuals leading to selection where one
might otherwise anticipate none. Secondly, a selection pressure
does not indicate whether an allele is significantly selected against
within a particular population. For a high enough effective
population size, even small negative selection can be sufficient to
Figure 4. Selection on late-onset diseases for the Ache and the modeled population. As in Figure 3C but using survival and fertility for Ache (left
panel) and the modeled population (right panel).
doi:10.1371/journal.pone.0001206.g004
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alleles involved in late onset diseases is likely to be generally under-
estimated. Alleles considered neutral or nearly neutral (for
mutation accumulation), or under negative selection small
enough to be traded-off for a positive effect at younger ages (for
antagonistic pleiotropy) may be more strongly negatively selected
than thought. For antagonistic pleiotropy (for which there is the
most empirical support, e.g., [30]), this implies that positive
selection on alleles associated with increases of survival or fertility
at young ages must be large enough to compensate for non-
negligible negative selection on survival at old ages, highlighting
the role of trade-offs in the evolution of senescence. For mutation
accumulation, purging of the genetic burden may be more
effective than hitherto suspected, suggesting a diminished role of
mutation accumulation in determining mortality late in life.
Although our results suggest diminished importance of mutation
accumulation in determining late-age mortality, they also provide
a strong counter-argument to one of its major criticisms.
Detractors of the theory of mutation accumulation argue that it
is unrealistic as an explanation of senescence because hazard rates
should go to infinity when the force of selection reaches zero (i.e.
after menopause), resulting in a wall of death (i.e. an age beyond
which there is no survival). Models incorporating intergenerational
transfers [31] or models considering the genetic inter-dependence
of males and females despite their demographic differences [32]
produce a more gradual decrease in the force of selection after
menopause, eliminating the possibility of this ‘‘wall of death’’
outcome. Additionally, here we show that simply considering
genetically associated variance in the age of onset of late-onset
diseases has a similar effect. In this respect, our results therefore
provide support for the theory of mutation accumulation.
Moreover, if our results prove true for a large number of diseases
affecting women at old ages, variance in the age of onset for these
diseases may explain extended post-reproductive life from
a genetic, rather then behavioral or cultural basis.
Future directions Initially, BRCA1 appears a good candidate
gene for testing the theory of mutation accumulation because 1)
when all BRCA1 mutations are taken together, the prevalence of
breast and ovarian cancer linked to the BRCA1 locus is one of the
highest among late-onset diseases and 2) in the absence of modern
medicine, the disease leads to rapid and certain death (as opposed
to slowly degenerative diseases, like Alzheimer dementia, whose
effects on fitness are unclear). However, we show that BRCA1
mutations are subject to strong negative selection. BRCA1 is
therefore not a good candidate for mutation accumulation. This is
also likely to be the case for other genetic susceptibilities where
allele frequencies are characterized by a large number of recent
and rare alleles, e.g. certain familial forms of coronary artery
diseases and Alzheimer dementia. Further tests of the hypothesis of
mutation accumulation might more fruitfully focus on diseases 1)
epidemiologically characterized by a very late and/or less variable
age of onset and/or 2) with an abundance of common and ancient
alleles. We hope that our study will encourage further research
using epidemiological data in a population genetics framework to
test evolutionary theories of aging.
SUPPORTING INFORMATION
Code S1 This code in ‘R’ allows calculations for steps 1,3 and 4.
Found at: doi:10.1371/journal.pone.0001206.s001 (0.05 MB
DOC)
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